Table 2.
Univariate analyses of community-acquired and nosocomial CDI
Community-onset n=55 (84.6%) | Nosocomial n=10 (15.4%) | P | OR (95% CI) | |
---|---|---|---|---|
Sex, n (%) | ||||
Female | 27 (49.1) | 6 (60) | 0.73 | 1.5 (0.4-6.13) |
Male | 28 (50.9) | 4 (40) | ||
Age groups, n (%) | ||||
18-28 | 15 (27.3) | 1 (10) | 0.003* | |
29-38 | 16 (29.1) | 0 | ||
39-48 | 15 (27.3) | 1 (10) | ||
49-58 | 3 (5.5) | 3 (30) | ||
59-65 | 3 (5.5) | 2 (31) | ||
>65 | 3 (5.5) | 3 (30) | ||
Presence of IBD, n (%) | 41 (74.5) | 3 (30) | 0.01* | 6.8 (1.5-30.08) |
Previous antibiotic use,** n (%) | 25 (45.5) | 9 (90) | 0.01* | 0.09 (0.01-0.78) |
Previous PPI use, n (%) | 22 (40) | 4 (40) | 1 | 1 (0.25-3.95) |
Immunosuppressive therapy, n (%) | 29 (52.7) | 4 (40) | 0.5 | 1.6 (0.42-6.64) |
Malignancy, n (%) | 2 (3.6) | 2 (31) | 0.1 | 0.15 (0.01-1.22) |
OR: Odds ratio; CI: Confidence interval; IBD: Inflammatory bowel disease; PPI: Proton pump inhibitor, *P≤0.05 was considered statistically significant, **Patients who used antibiotics in last 3 months